Ritchie Shawn A, Chitou Bassirou, Zheng Qingan, Jayasinghe Dushmanthi, Jin Wei, Mochizuki Asuka, Goodenowe Dayan B
Shawn A Ritchie, Bassirou Chitou, Dushmanthi Jayasinghe, Department of Biomarker Discovery and Validation, Phenomenome Discoveries, Saskatoon, SK S7N 4L8, Canada.
World J Gastroenterol. 2015 Jun 7;21(21):6604-12. doi: 10.3748/wjg.v21.i21.6604.
To investigate serum PC-594 fatty acid levels as a potential biomarker in North American pancreatic cancer (PaC) patients, and to compare its performance to CA19-9.
Using tandem mass spectrometry, we evaluated serum PC-594 levels from 84 North American patients with confirmed PaC and 99 cancer-free control subjects. We determined CA19-9 levels by ELISA. Significance between PaC patients and controls, and association with clinical variables was determined by analysis of variance and t-tests. Diagnostic performance was evaluated by receiver-operator characteristic (ROC) curve analysis, and PC-594 correlation with age and CA19-9 determined by regression analysis.
Mean PC-594 levels were 3.7 times lower in PaC patients compared to controls (P < 0.0001). The mean level in PaC patient serum was 0.76 ± 0.07 μmol/L, and the mean level in control subjects was 2.79 ± 0.15 μmol/L. There was no correlation between PC-594 and age, disease stage or gender (P > 0.05). Using 1.25 μmol/L as a PC-594 threshold produced a relative risk (RR) of 9.4 (P < 0.0001, 95%CI: 5.0-17.7). The area under the receiver-operator characteristic curve (ROC-AUC) was 0.93 (95%CI: 0.91-0.95) for PC-594 and 0.85 (95%CI: 0.82-0.88) for CA19-9. Sensitivity at 90% specificity was 87% for PC-594 and 71% for CA19-9. Six PaC patients with CA19-9 above 35 U/mL showed normal PC-594 levels, while 24 PaC patients with normal CA19-9 showed low PC-594 levels. Eighty-five of the 99 control subjects (86%) showed normal levels of both markers.
PC-594 biomarker levels are significantly reduced in North American PaC patients, and showed superior diagnostic performance compared to CA19-9.
研究血清PC-594脂肪酸水平作为北美胰腺癌（PaC）患者潜在生物标志物的可能性，并将其性能与CA19-9进行比较。
我们使用串联质谱法评估了84例确诊为PaC的北美患者和99例无癌对照受试者的血清PC-594水平。通过酶联免疫吸附测定法（ELISA）测定CA19-9水平。通过方差分析和t检验确定PaC患者与对照组之间的差异以及与临床变量的关联。通过受试者操作特征（ROC）曲线分析评估诊断性能，并通过回归分析确定PC-594与年龄和CA19-9的相关性。
与对照组相比，PaC患者的平均PC-594水平低3.7倍（P < 0.0001）。PaC患者血清中的平均水平为0.76±0.07μmol/L，对照受试者中的平均水平为2.79±0.15μmol/L。PC-594与年龄、疾病阶段或性别之间无相关性（P > 0.05）。以1.25μmol/L作为PC-594阈值时，相对风险（RR）为9.4（P < 0.0001，95%CI：5.0 - 17.7）。PC-594的受试者操作特征曲线下面积（ROC-AUC）为0.93（95%CI：0.91 - 0.95），CA19-9为0.85（95%CI：0.82 - 0.88）。在90%特异性时，PC-594的灵敏度为87%，CA19-9为71%。6例CA19-9高于35 U/mL的PaC患者PC-594水平正常，而24例CA19-9正常的PaC患者PC-594水平较低。99例对照受试者中有85例（86%）两种标志物水平均正常。
北美PaC患者的PC-594生物标志物水平显著降低，且与CA19-9相比显示出更好的诊断性能。
